Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alan Durkin

Plastic and Reconstructive Surgery Vero Beach, FL Medical Doctor

NPI 1215136767 CMS profile 145509

5070 Highway A1a, Suite A, Vero Beach, FL 32963

Open in the dashboard

General payments

$547,847

575 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,585 paid to institutions, not to them · program year 2019

Through program year 2025, Alan Durkin of Vero Beach, FL is reported in the CMS Open Payments database as having received $547,847 across 575 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,585 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,499 42
2024 General $66,133 41
2023 General $160,508 113
2022 General $168,440 133
2021 General $53,515 65
2020 General $31,282 39
2019 General $50,469 142

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alan Durkin
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Alan Durkin were reported at $17,499. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Alan Durkin Plastic and Reconstructive Surgery median Middle half National median
2019 $50,469 $335 $121–$1,264 $163
2020 $31,282 $162 $57–$417 $114
2021 $53,515 $245 $89–$735 $132
2022 $168,440 $325 $120–$932 $149
2023 $160,508 $343 $129–$999 $160
2024 $66,133 $390 $141–$1,085 $164
2025 $17,499 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Musculoskeletal Transplant Foundation Inc. $337,501 104 payments
  2. Merz North America, Inc. $192,088 331 payments
  3. Allergan Inc. $10,150 58 payments
  4. AbbVie, Inc. $5,121 20 payments
  5. Mentor Worldwide LLC $625 22 payments
  6. Medela LLC $561 6 payments
  7. Revance Therapeutics, Inc. $416 3 payments
  8. Integra LifeSciences Corporation $351 3 payments
  9. Galderma Laboratories, L.P. $184 11 payments
  10. Avita Medical Americas, LLC $150 1 payment
  11. Other $700 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $449,136 92 payments
  2. Travel and Lodging $30,624 71 payments
  3. Food and Beverage $26,915 385 payments
  4. Gift $22,950 4 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,500 3 payments
  6. Grant $4,450 1 payment
  7. Education $946 18 payments
  8. Long term medical supply or device loan $326 1 payment
Products named General payments · program years 2019–2025
  1. Xeomin Dermatology $71,702 172 payments
  2. Xeomin musculoskeletal $17,304 23 payments
  3. NATRELLE $9,674 32 payments
  4. (Plus) $5,625 9 payments
  5. BOTOX $4,848 15 payments
  6. ASCLERA $2,735 38 payments
  7. Invia Motion Endure $561 6 payments
  8. MENTOR MemoryGel Resterilizable Gel Sizer $549 18 payments
  9. DAXXIFY $416 3 payments
  10. ARTOURA Breast Tissue Expander $399 17 payments
  11. Other $2,234 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

160

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$1,070

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

92.5%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 71 $569
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 49 $286
Valacyclovir Valacyclovir Hcl Brand 16 $97
Ciprofloxacin Hcl Generic 12 $67
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$51,891

Medicare's payments for the services billed

Medicare patients

93

Average age 76

Services billed

220

52 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 55%
Atrial fibrillation 20%
Cancer 19%
Ischemic heart disease 18%
Depression 17%
Chronic kidney disease 16%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xeomin
  • MERZ NORTH AMERICA, INC. $4,970
$4,970 — —
BOTOX
  • AbbVie, Inc. $4,450
$4,450 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

575 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record